The multidrug resistance (MDR) phenotype is a major cause of cancer treatment failure. Here the expressions of 4224 genes were analysed for association with intrinsic or acquired doxorubicin (DOX) resistance. A cluster of overexpressed genes related to DOX resistance was observed. Included in this cluster was ABCB1 the Pglycoprotein transporter protein gene and MMP1 (Matrix Metalloproteinase 1), indicative of the invasive nature of resistant cells, and the oxytocin receptor (OXTR), a potential new therapeutic target. Overexpression of genes associated with xenobiotic transformation, cell transformation, cell signalling and lymphocyte activation was also associated with DOX resistance as was estrogen receptor negativity. In all carcinoma cells, compared with HBL100 a putatively normal breast epithelial cell line, a cluster of overexpressed genes was identi®ed which included several keratins, in particular keratins 8 and 18 which are regulated through the ras signalling pathway. Analysis of genomic ampli®cations and deletions revealed speci®c genetic alterations common to both intrinsic and acquired DOX resistance including ABCB1, PGY3 (ABCB4) and BAK. The ®ndings shown here indicate new possibilities for the diagnosis of DOX resistance using gene expression, and potential novel therapeutic targets for pharmacological intervention. Oncogene (2001) 20, 1300 ± 1306.
Introduction
Exposure of cells to increasing concentrations of the cytotoxic anticancer drug doxorubicin (DOX) in vitro leads to development of cells with a multidrug resistant (MDR) phenotype (Chen et al., 1994) . In the majority of cases DOX resistant cells display a cross resistance to other chemotherapeutic agents that correlates to over-expression of the P-glycoprotein membrane transport protein coding gene ABCB1 (Gottesman and Pastan, 1993) . However the development of a full MDR phenotype is not likely to be due to the dierential expression of one gene alone but rather to the in¯uence of many genes that can protect against the drug itself by many mechanisms including increased extrusion from the cell, metabolism, phase II conjugation and DNA damage repair. Also, gene expression may be altered such that, for example, the cellular response to drug exposure, cell death, apoptosis or senescence is reduced. All of the genes involved with the MDR phenotype and dierential responses to drug exposure are downstream genes, and as such are likely to be subject to regulation by upstream genes that may themselves be dierentially expressed. The most feasible way at the present time to examine many genes simultaneously and get a picture of their contribution to the MDR phenotype, response to drug exposure and networks of regulatory gene control is to use cDNA microarray analysis.
Therefore in this study we used cDNA microarrays to examine the dierential gene expression patterns associated with the MDR phenotype and compared these with a similar analysis in a variety of other breast carcinoma cell lines. We further used the dierential gene expression data set to test the hypothesis that tumours with an acquired MDR phenotype are derived by the selection of cells with an intrinsic MDR phenotype under pressure of chemotherapy by matching gene expression patterns from cells with acquired or intrinsic DOX resistance. The acquired DOX resistant cells (HPGP) have been previously described and were selected from an MCF7WT progenitor stock by an increasing concentration of DOX followed by FACS cell sorting (Davies et al., 1996) . For comparison an intrinsically DOX resistant cell line was selected using the MRK16 antibody and magnetic bead cell sorting from the progenitor drug sensitive cell line MDA468. MRK16 binds the ®rst and fourth extracellular loops of the ABCB1 gene product Pglycoprotein (Vasudevan et al., 1998) . Thus these cells, called MDA16, were selected for a DOX resistant phenotype without use of cytotoxic drug selection pressure. The results presented here show clusters of gene expression associated with the DOX resistant phenotype, some of which correlate with phenotypic features of the cells. There was also a correlation of both gene expression and genomic alteration between the cells with acquired and intrinsic DOX resistance.
Results

Gene expression associated with the DOX resistant phenotype
Cell lines with varying degrees of intrinsic and acquired resistance to DOX were investigated for dierential gene expression amongst a cohort of 4224 named human genes using microarray technology. DOX resistance was determined by measuring cell viability using the MTT+ assay after exposure to a ®ve order range of DOX concentrations over a 4 day period (Figure 1 ). The two most DOX sensitive cell lines (based on the 50% loss of viability over 4 days) were the MDA468 cells from which the intrinsic line MDA16 was derived and the putatively normal breast cell line HBL100 which was used for comparison with all the other cell lines. Amongst the cell lines regarded as DOX sensitive (all those except MDA16 and HPGP) there was an order of magnitude dierence in DOX sensitivity using the 50% loss of viability measure, with the BT474 cell line being the most resistant (Figure 1b) . A 50% loss of viability was not achieved in either of the DOX resistant cell lines, MDA16 or HPGP, over the DOX concentration range used here ( Figure  1) .
Clusters of dierential gene expression associated with DOX resistance for both the intrinsically resistant MDA16 cells and the HPGP cells with acquired DOX resistance are shown in Figure 2 . The full dataset with the ConvertData program are available at http://www.le.ac.uk/cmht/twgl/array-fp.html. As well as the DOX resistant cell progenitors MCF7WT and MDA468 the DOX sensitive, putatively normal mammary cell line, HBL100 was used for comparison against all cell lines. Clustering analysis using the expression scores ascribed to each gene, as described in Materials and methods, was performed using the hierarchical clustering algorithms selected by Eisen et al. (1998) . Across the dierent cell pairs HPGP (acquired resistance) and the intrinsically resistant MDA16 cells clustered together when analysed against their drug sensitive progenitors (Figure 2 ± red box) and also when compared for dierential gene expression against the unrelated, putatively normal mammary cell line HBL100 (Figure 2 ± green box). These dierential gene expressions fell into two main groups those associated with DOX resistance (Figure 2a) , and those associated with a dierential cell type (Figure 2b and  3a) .
Genes overexpressed in both the intrinsic and acquired DOX resistant cell lines are shown in Figure  2a . Unsurprisingly one of the major genes seen overexpressed here was ABCB1 that was both overexpressed and ampli®ed (genomic hybridizations are indicated by the blue box). Included in this cluster is MMP1 (Matrix metalloproteinase 1). The protein product of the MMP1 gene is associated with invasion of tumour cells into surrounding tissue (Benbow et al., 1999) .
Another gene increased in expression in the DOX resistant cells was MSLN (pre-pro-megakaryocyte potentiating factor), otherwise known as mesothelin (Figure 2a ). This gene has been previously described for its over expression in ovarian cancers and mesothelioma cells (Chang and Pastan, 1996) . A similar expression pro®le for the LSP1 (lymphocyte speci®c protein 1) ( Figure 2a ) and CD63 genes was observed. The LSP1 gene was originally isolated from T-lymphocytes and though its function is not con®rmed it is thought to be involved with transmembrane signalling. It is downregulated in cells undergoing apoptosis (Brockstedt et al., 1998) and thus its overexpression in the DOX resistant cells suggests that these cells also may be resistant to apoptosis. Resistance to apoptosis has been previously associated with increased ABCB1 gene expression (Robinson et al., 1997) . The CD63 gene encodes the melanoma 1 antigen and may be involved with growth regulation in the early stages of melanoma tumour progression. It has previously been described as being an oestrogen responsive gene in breast cancer cells (Stephen et al., 1998) and it was therefore surprising to ®nd it highly expressed in the DOX resistant cells which were oestrogen receptor negative.
Differential expression of the Oxytocin receptor in DOX resistant phenotype cells
Increased expression of the OXTR (Oxytocin receptor) in both DOX resistant cell types in comparison to their drug sensitive progenitors was observed ( Figure 2a ). This receptor is normally overexpressed in the uterus just before the onset of labour and in myo-epithelium where it allows responsiveness to oxytocin for milk ejection during lactation. Overexpression of the OXTR has been previously reported in endometrial adenocarcinomas (Cassoni et al., 2000) .
Differentially expressed genes in breast carcinoma associated with a transformed phenotype
Genes overexpressed in all the carcinoma cells relative to HBL100 are shown in the cluster of Figure 3a and also in the individual representations in Figure 3b ,c. There was an abundance of keratin genes in this cluster. Overexpression of keratin 18 has been previously noted in a study of breast carcinoma cells using microarrays (Perou et al., 1999 (Perou et al., , 2000 . This protein dimerizes with keratin 8 that was also overexpressed in these cells. Over-expression of the keratin genes relative to HBL100 was maintained in the DOX resistant cells.
Gene amplifications and deletions in DOX resistant cells compared with their drug sensitive progenitors
Gene ampli®cations and deletions in the DOX resistant and sensitive cell pairs are shown in Figure 2d with the exception of ABCB1 that is in Figure 2a . Of the six ampli®ed genes only ABCB1 and HNRPA1 (heterogeneous nuclear ribonucleoprotein A1) genes were also overexpressed (Figure 2a and d) . Ampli®cation of the ABCB1 gene has been previously described as occurring in mammalian MDR phenotype cells (Shen et al., 1986; Fairchild et al., 1987; Van der Bliek et al., 1988) and in vitro precedes the MDR phenotype under selection pressure (Shen et al., 1986) . Ampli®cation of PGY3 (ABCB4), the non-resistance coding form of the MDR gene family was also observed. The ABCB4 gene is located alongside ABCB1 on chromosome 7 and its ampli®cation in a cassette form with the ABCB1 gene has been previously recognised. Ampli®cation of the BAK1 gene was also observed, though as with the ABCB4, increased expression was not seen. BAK1 is located on chromosome 6p21 and has not been previously correlated with a drug resistance phenotype. As it was not overexpressed in these cells it was not contributing to the phenotype. Interestingly in the HPGP cells (acquired resistance) ampli®cation of BCL-2 was also observed (Figure 2d ). The protein product of this gene forms heterodimers with BAK1. However, as neither of these genes was also overexpressed the signi®cance of this is unclear though there may be a relationship with four ABC genes (ABCC10, ABCF1, ABCB2 and ABCB3) that are located in this region of chromosome 6 (Klucken et al., 2000) . The occurrence of this ampli®cation in both the acquired and intrinsically resistant phenotypes indicates it may be a pre-requisite for the development of a MDR phenotype, which is then selected for by DOX exposure.
Expression of GSTp (GSTP1) in the DOX resistant cells
Expression of GSTp has previously been associated with overexpression of ABCB1 and with acquired resistance to DOX (Batist et al., 1986) . The expression pattern of GSTp in these cell pairs is shown in Figure  2b . As expected, overexpression of GSTp was highest in the acquired DOX resistant HPGP cells, but also in the intrinsically DOX resistant MDA16 cells relative to their drug sensitive progenitors. The putatively normal cell breast carcinoma cell line HBL100 also had an elevated GSTp expression compared with MCF7WT cells.
Oestrogen receptor status
Expression of ESRa (estrogen receptor a) was reduced in HPGP cells compared with its progenitor MCF7WT cell line which is ESRa positive (Figure 3d ). There was no dierential expression of ESRa between the MDA16 cells and their drug sensitive progenitors the MDA468 cell line. As the MDA468 cell is oestrogen receptor negative this merely con®rmed that the intrinsically resistant MDA16 cells had maintained this phenotype. The putative mammary epithelial cell line HBL100 also had decreased ESRa gene expression compared with MCF7WT cells (Figure 3d ). This ®nding can be seen con®rmed in the HBL100/ MDA16 and HBL100/HPGP cell pairs where the unchanged gene expression indicates the ESRa negative status of both cell lines. The ESRa negative status of the HBL100 cells is con®rmed by other reports (Bamberger et al., 1999) .
Discussion
In this study we used cDNA microarrays to analyse dierential gene expression in breast carcinoma cells with both intrinsic and acquired DOX resistant phenotypes. The dierential expressions of individual genes were interesting in their own right with some expected increases in expression, for example of the ABCB1 gene, and some which could be related to phenotypic properties, for example MMP1. For some of the other genes their speci®c expression in the DOX resistant cells suggest that they may present opportunities as new therapeutic targets. As a whole the data set was used to test the hypothesis that tumours with an acquired MDR phenotype are derived by the selection of a sub population of cells with an intrinsic multidrug resistant phenotype under pressure of chemotherapy. This is a dicult analysis as there are no clear criteria for what constitutes a pattern match in an expression analysis of a large number of genes. Additionally, in gene subsets of the total genome there will inevitably be inaccuracy in a pattern matching analysis as some genes may not be present that would either support, or detract from, the pattern match. Therefore, the level of correlation that constitutes similarity should depend on the set of genes selected. However, even with this caveat it can still be seen that there is a high level of similarity in the clusters of dierentially expressed genes associated with intrinsic and acquired DOX resistance that substantially indicates a degree of cell similarity. These data thus support the hypothesis that those cells selected by exposure to DOX gained their MDR phenotype as a result of spontaneous mutation, followed by drug selection, rather than through DOX mediated alteration of gene expression.
Using cDNA arrays Martin et al. (2000) have shown that breast carcinoma cells can be separated into two very dierent cell types based on their ESRa status characterised by widespread dierences in gene expression. These authors did not speci®cally recognise the ABCB1 gene in the cluster of genes associated with an ESRa negative status, but also did not include MDR phenotype cells in the study. The data presented here strongly indicates that DOX resistance, and ESRa negative status are linked. This has profound implications for the treatment of chemotherapy resistant disease with oestrogen receptor antagonists where these compounds may be ineective even in the absence of prior exposure.
Included in the DOX resistance cluster of genes overexpressed in both acquired and intrinsic DOX resistant cells was the MMP1 gene. This gene is involved in metastasis and invasion, and cells with an MDR phenotype have been previously reported to also have an increased invasive ability. Therefore the increased expression of MMP1 in the DOX resistant cells was consistent with this recognised characteristic (Weinstein et al., 1991) . Other genes speci®cally expressed in this cluster oer potential as therapeutic targets for example OXTR that was speci®cally expressed in the DOX resistant cells. This receptor is expressed physiologically very speci®cally and so its expression in the DOX resistant cells oers the possibility for therapeutic intervention. In the human endometrial OXTR positive cell line (COLO684) growth is retarded in the presence of oxytocin (Cassoni et al., 2000) . Oxytocin is also able to reduce growth in the MDA-MB231 cells (Cassoni et al., 1997) , and therefore oxytocin may have a greater eect on MDR phenotype cells with a very high level of OXTR expression, than drug sensitive cells, and thus may be useful in treatment design.
Two genes overexpressed in melanoma are included in the DOX resistance cluster, CD63 and PRAME (preferentially expressed antigen in melanoma). PRAME and another gene in this cluster, NK4 (natural killer cell transcript 4) are involved with lymphocyte activation and thus may be of relevance in immunologically mediated cancer chemotherapy. The same is possibly true for LSP1 though the function of this gene is not well characterized. There is expression of a number of genes associated with metabolic transformation of xenobiotics, e.g.: GSTp and NNMT (nicotinamide N-methyltransferase). The enhanced transformation of xenobiotics provides another mechanism by which the cells may confer upon themselves a higher level of resistance. Finally the overexpression of GM2A (ganglioside activator protein) is of relevance. This protein is involved with the breakdown of glycosphingolipids, and there is an association between P-glycoprotein overexpression and glycosphingolipid accumulation (Lala et al., 2000) . Therefore overexpression of a gene involved with the breakdown of sphingolipids in DOX resistant cells is not surprising, though previously unreported.
The overexpression of keratins 4, 7, 8, 14 and 18 was seen in the carcinoma cell lines relative to the putatively normal cell line HBL100. Expression of keratins 8 and 18 is a characteristic feature of luminal epithelial cells and also may be indicative of the carcinoma cells having some de-dierentiated stem cell like characteristics. Overexpression of keratinin 14 has been noted in a recent array study of breast cancer (Martin et al., 2000) and was associated with tumor size. Regulation of keratins 8 and 18 through the ras signalling pathway has been reported (Oshima et al., 1996) . In this study the greatest increase in expression of both keratins 8 and 18 was in the ESRa positive cell lines MCF7WT and ZR75-1 relative to the HBL100 cell line, and in these comparisons there was a signi®cant increase in Nras expression in the MCF7WT and ZR75-1 cells (data not shown, available as supplementary data).
Hanahan and Weinberg (2000) have suggested six essential alterations in cell physiology which dictate malignant growth, each of which can be de®ned by the dierential expression of sets of genes. The ®rst of these is endogenously regulated growth exempli®ed by increased expression of genes such as epidermal growth factor receptor. We saw a changed expression of several growth signals, for example CTGF (connective tissue growth factor) in ZR75-1 cells relative to both MCF7WT and HBL100 (supplementary web site data). There was an increased expression of TGFb1 in both MDR cell lines relative to their progenitors (Figure 2c) . Similarly, ZR75-1 cells also displayed increased expression of MAPK6 (supplementary web site data) that may indicate decreased cell cycle regulation in these cells.
The evasion of apoptosis is another feature of cancer cells and evidence of this within many of these cells is demonstrated by the dierential expressions of several genes, in particular IGFBP5 (insulin growth factor binding protein 5) (supplementary web site data) (Blatchford et al., 1999) . Finally, invasive potential is a fundamental characteristic of cancer cells and in this regard the upregulated expression of MMP1 is shown in Figure 2a . The dierential expression of integrins to facilitate binding to degraded stroma is another feature of metastasis in breast carcinoma (Jones and Walker, 1997). Here we observed a very signi®cant upregulation of integrin B4 in MCF7WT, T47D and both DOX resistant cell types relative to HBL100 (web site supplementary data) suggesting an increased propensity to metastasis.
In summary, microarrays have the potential to assist in diagnosis through linking of particular gene expression patterns with pathological change in disease states, and to provide an ongoing picture of phenotypic alterations during treatment. This has been previously indicated in the studies of Perou et al. (1999 Perou et al. ( , 2000 , Alizadeh et al. (2000) and Martin et al. (2000) . Here we have used microarrays to identify a dierential gene expression pattern associated with both acquired and intrinsic DOX resistant phenotypes in breast cancer cells. There was additionally a common alteration in genotype consisting of an ampli®cation of a small set of ®ve genes. Such a gene expression pattern would provide a useful diagnostic marker of DOX resistance in untreated tumours and its development during chemotherapy. Some of the genes in the DOX resistance cluster may prove to be useful chemotherapeutic targets for the treatment of DOX resistant carcinomas.
Materials and methods
Assessement of toxicity
Toxicity was assessed using the MTT + assay in kit form (Promega) following the manufacturers instructions and using a 4 day exposure to DOX. 100 000 cells were initially plated in each well of a 96 well plate and grown in 100 ml of medium with the appropriate DOX concentration in 0.1% DMSO. The cells were allowed an attachment period of 4 h after seeding before exposure to the DOX commenced. After 2 days the media were changed and fresh DOX added to the same concentration. After 4 days the number of viable cells was assess using the MTT assay kit according to the manufacturers instructions.
Production of the 4224 gene array
Four thousand of the EST clones were obtained from Research Genetics (Human known gene set) (http://www.resgen.com). The remainder were added by selection from GenBank: the actual clones were obtained from the IMAGE collections held at the MRC Human Gene Mapping Project (http://www.hgmp.mrc.ac.uk/). These clones were sequence veri®ed prior to arraying. All of the plasmid inserts were ampli®ed by use of a universal primer set and a standard PCR mix (ABGene) employed. The products were all electrophoresed on an agarose gel and the gel images stored for future reference. A second microarray containing 6000 genes (the previous 4224 with more added from the IMAGE clone collections) was also utilized for some of the work. In order to merge these results with those from the 4224 gene array, data pertaining to genes that were not common between the two arrays were removed prior to analysis.
All PCR products that failed in initial ampli®cation or produced multiple bands were re-ampli®ed using plasmid speci®c primers. The size of the insert sequence was determined from the agarose gel by comparison with the ladder using MultiAnalyst software (BioRad). After PCR the reaction products were precipitated and prepared for array using the methods described by Eisen and DeRisi (DeRisi et al., 1997; Eisen et al., 1999) .
Printing of the array and hybridization
Arrays were printed on poly-L-lysine coated slides and UV crosslinked and blocked prior to use as previously described (DeRisi et al., 1997; Eisen and Brown, 1999) . The arrays were printed using an arrayer built essentially according to the Stanford designs and can be seen at http://www.le.ac.uk/ cmht/twg1/array-fp.html. The centre to centre distance of the features was 210 mm and each feature was 90 ± 100 mm in diameter.
Labelling and hybridization
RNA labelling
Labelling was carried out essentially as described by DeRisi et al. (1997) and Eisen and Brown (1999) . Priming was achieved using a oligo dT (25) using 4 mg with 50 mg of total RNA. After denaturation at 708C for 8 min annealing was allowed to occur as the temperature fell to 428C over 30 min. At this point dNTPs (Pharmacia) were added to ®nal concentrations of 0.5 mM with the exception of dTTP which was at 0.2 mMM. The desired Cy labelled dUTP (Amersham) was added to a ®nal concentration of 0.1 mM. The buer was 16 ®rst strand buer (Gibco/BRL)and 20 U of RNAsin was added to the reaction. Transcription was initiated by the addition of Superscript II 100 U (Gibco/BRL) and allowed to proceed for 1 h at 428C before addition of a second 100 U of Superscript II and another 1 h incubation at 428C.
RNA was removed from the synthesized cDNA by addition of NaOH/EDTA/SDS to ®nal concentrations of 0.195 M/10 mM/0.22% and incubated at 688C for 30 min and 258C for 15 min. The reaction was neutralized by addition of HCl and buered to pH 7.5 by addition of Tris/HCl. The reaction was puri®ed by passage through a Centristep column (Princeton separations).
DNA labelling
Two mg of genomic DNA was restricted using dpnII (New England Biolabs.) (50 units for 2 h at 378C) and then extracted twice with 1 : 1 phenol chloroform followed by 100% chloroform and sodium acetate/ethanol precipitation. Labelling was achieved using random hexamers as described by Feinberg and Vogelstein (1983) but using 50 U Klenow fragment (1 ml of 50 000 U/ml New England Biolabs) and 0.08 mM Cy labelled dCTP. Labelling was allowed to proceed overnight at 258C. After labelling the product was puri®ed using Centristep columns as described for the RNA and hybridized as described below but omitting the poly A (80) from the hybridization mixture and hybridization time was extended to 48 h.
Hybridisation
Hybridization was carried out in humidi®ed chambers at a temperature of 428C for approximately 16 h. The hybridization buer consisted of 50% deionised formamide/0.5% SDS/66 SSPE and 2.56 Denhardts/0.06 mg/ml of poly A (80) / 0.66 mg/ml Human Cot 1 DNA/0.27 mg/ml yeast tRNA. The arrays were washed in 1.06SSC, 0.03% SDS by plunging in several times until the coverslip fell o and then transferred to 0.26SSC and plunged again several times followed by a ®nal wash in 0.056SSC at room temperature.
Analysis of fluorescence and data processing
Fluorescence was measured using the GenePix 3.0 (version 3.0.0.85) software (Axon Instruments). Feature sizes were determined using the inbuilt automated parameters in the ®rst instance and then adjusted manually where appropriate. The¯uorescence of each pixel within the feature was determined and the median¯uorescence of these pixel measurements taken as the measure of¯uorescence for the whole feature. The local background¯uorescence was measured using the default parameters of GenePix 3.0.
The raw feature data for each channel were globally centred by reference to the median¯uorescence of the whole feature set for that channel. The mean6s.d. of the log 2 ratio data was calculated, and used to calculate a signi®cance weighting value using the following equation: f(x)=1/(1+EXP(7a(x7b))) where x=log 2 ratio, a=5/(conf997conf95) and b=(conf95+conf99)/2. The signs of the function and con®dence values were reversed for the two tails of the distribution. Values between 0.05 and 70.05 were rounded to 0. Signi®cance weighting values greater than 0.92, or less than 70.92, were associated with dierential expression ratios falling in the greater than 99% con®dence levels in both tails of the distribution. Thus, the middle signi®cance weighting value of 0.5 was associated with the values falling on the 97.5% con®dence value and the whole data set was thus normalized to a scale of 71 to 1. Clustering analysis was performed using the signi®cance weighting.
For clustering analysis data from replicate experiments were entered separately. Data for which there was ā uorescence value in one channel only were treated as a special case. These values were assigned a signi®cance value of +1 or 71 depending on which channel the¯uorescence was recorded and only if the intensity of that¯uorescence was greater than a multiple of 0.5 to three (dependent on the array quality) times the average¯uorescent intensity for the channel as a whole. Data processing was carried out using ConvertData version 3.2.3a (latest version available at http:// www.le.ac.uk/cnht/twg1/array-fp.html). These values were fed into cluster3 (Eisen ± http://www-genome.stanford.edu/) (Eisen et al., 1998) and clustered hierarchically using complete linkage. Prior to viewing the weighted signi®cance data were converted back into ratio data. The clustering data were displayed using Treeview http://www.rana.lbl.gov. The density of colour indicates the ratio as indicated in the ®gure key. The integrity of the data for 96 genes was checked using nylon arrays of the gene products and 33 P RNA labelling. These genes were spread equally between those over, under and not dierentially expressed as determined by¯uorescence labelling and hybridisation on microarrays. There was a good correlation between the gene expressions determined bȳ uorescent and 33 P labelled methods using glass and nylon based array respectively (data not shown).
